<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381301</url>
  </required_header>
  <id_info>
    <org_study_id>METC 14-4-117</org_study_id>
    <nct_id>NCT02381301</nct_id>
  </id_info>
  <brief_title>Biomarkers and Cardiac CT</brief_title>
  <official_title>Biomarkers and Cardiac Computed Tomography: Relationship Between Cardiovascular Biomarkers and Coronary Artery Disease in Patients Undergoing Cardiac Computed Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed
      countries. In addition, many patients suffer from valvular and aortic disease. Although
      various tools are available to identify patients with cardiovascular (CV) disease at risk for
      major adverse cardiac events (MACE), the identification of these patients remains a clinical
      challenge.

      One promising avenue is the use of different serum biomarkers involved in atherothrombosis
      which could provide an easy and cost-effective step in risk stratification.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Data registration of patients undergoing CCTA and given written informed consent.</measure>
    <time_frame>15 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To detect these patients for cardiovascular disease and Long term CV outcome (MACE).</measure>
    <time_frame>15 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relationship of novel blood biomarkers with CCTA findings.</measure>
    <time_frame>15 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The predictive value of these biomarkers to predict CAD in patients undergoing CCTA.</measure>
    <time_frame>15 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prognostic value of these biomarkers (in combination) to predict MACE.</measure>
    <time_frame>15 years.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Venous blood sampling prior to CCTA.</arm_group_label>
    <description>In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Venous blood sampling prior to CCTA.</intervention_name>
    <arm_group_label>Venous blood sampling prior to CCTA.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred from the Cardiology clinic for routine CCTA for diagnostic purposes, will
        be included in this study, after given written informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred from the Cardiology clinic for routine CCTA.

        Exclusion Criteria:

          -  Pregnancy

          -  Severe renal insufficiency

          -  Severe allergy to contrast medium

          -  Inability to obtain informed consent

          -  Age below 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry J Crijns, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bas Kietselaer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bas Kietselaer, MD, PhD</last_name>
    <phone>+31433871587</phone>
    <email>b.kietsealer@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sibel Altintas, MD</last_name>
    <phone>+31433881232</phone>
    <email>s.altintas@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bas L Kietselaer, MD, PhD</last_name>
      <email>b.kietselaer@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biological Markers</keyword>
  <keyword>Multidetector Computed Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

